Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16454357 | 0.80 | KMT2A (0.36) | CYP1A2CYP2D6ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL20122655 | 0.80 | CYP1A2 (0.37) | CYP1A2CYP2D6ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL19190828 | 0.79 | CYP1A2 (0.37) | CYP1A2CYP2D6ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL278866 | 0.78 | CA2 (0.37) | HSD17B10 | |
| SCHEMBL7717522 | 0.78 | CYP1A2 (0.50) | CYP1A2CYP2D6ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL19068905 | 0.77 | CYP1A2 (0.35) | CYP1A2CYP2D6ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL17300766 | 0.77 | JAK3 (0.39) | ELOVL1 | |
| SCHEMBL11960342 | 0.76 | POLB (0.44) | ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL21091671 | 0.74 | CNR2 (0.34) | CYP1A2CYP2D6ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL17688925 | 0.73 | PTGS2 (0.45) | ALDH1A1HSD17B10TP53TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-9963445-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2018-05-08 | — | — | US | disclosed |
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2017-11-02 | — | — | US | disclosed |
| US-20160159781-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313712-A1 | DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | HDAC1, HDAC11, HDAC7 | CYP1A2 3148/4885CYP2D6 3175/4885ALDH1A1 1057/4885 |
| US-20160159781-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | CYP1A2 22/4885CYP2D6 150/4885ALDH1A1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.